Advertisement

Related Videos

David A. Hyman, MD, JD, on Inclusive Shared Savings

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Peter Clark, MA, MD, FRCP: A Payer Perspective

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Advertisement

Advertisement




Aug
15
Today In Oncology
What Is the Optimal PSA to Determine Prostate Cancer Treatment Efficacy
Can Newborn Genetic Testing Identify Cancer Predisposition Genes
FDA Approves CELMoD Combination Regimen for Pretreated Multiple Myeloma
Cretostimogene Grenadenorepvec in BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer
QOL Impact of Postmastectomy Chest Wall Radiotherapy 5-Year Follow-up
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo